Related references
Note: Only part of the references are listed.Murine double minute 2 inhibition alone or with cytarabine in acute myeloid leukemia: Results from an idasanutlin phase 1/1b study
Karen Yee et al.
LEUKEMIA RESEARCH (2021)
Persistent leukocytosis in polycythemia vera is associated with disease evolution but not thrombosis
Lukas Ronner et al.
BLOOD (2020)
Long-term efficacy and safety of ruxolitinib versus best available therapy in polycythaemia vera (RESPONSE): 5-year follow up of a phase 3 study
Jean-Jacques Kiladjian et al.
LANCET HAEMATOLOGY (2020)
Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study
Heinz Gisslinger et al.
LANCET HAEMATOLOGY (2020)
TP53 mutations in myelodysplastic syndromes and secondary AML confer an immunosuppressive phenotype
David A. Sallman et al.
BLOOD (2020)
Polycythemia vera and essential thrombocythemia: 2021 update on diagnosis, risk-stratification and management
Ayalew Tefferi et al.
AMERICAN JOURNAL OF HEMATOLOGY (2020)
MDM2 inhibition: an important step forward in cancer therapy
Marina Konopleva et al.
LEUKEMIA (2020)
The advantages and risks of ruxolitinib for the treatment of polycythemia vera
Gioia Colafigli et al.
EXPERT REVIEW OF HEMATOLOGY (2020)
Transient expansion of TP53 mutated clones in polycythemia vera patients treated with idasanutlin
Bridget K. Marcellino et al.
BLOOD ADVANCES (2020)
Oral idasanutlin in patients with polycythemia vera
John Mascarenhas et al.
BLOOD (2019)
Pegylated interferon alfa-2a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyurea
Abdulraheem Yacoub et al.
BLOOD (2019)
A Randomized, Open-Label, Multicenter, Phase 2 Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of KRT-232 Compared with Ruxolitinib in Patients with Phlebotomy-Dependent Polycythemia Vera
Jason Gotlib et al.
BLOOD (2019)
Splenomegaly impacts prognosis in essential thrombocythemia and polycythemia vera: A single center study
Vincenzo Accurso et al.
HEMATOLOGY REPORTS (2019)
A computational approach to distinguish somatic vs. germline origin of genomic alterations from deep sequencing of cancer specimens without a matched normal
James X. Sun et al.
PLOS COMPUTATIONAL BIOLOGY (2018)
Classification and Personalized Prognosis in Myeloproliferative Neoplasms
J. Grinfeld et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
The BCR-ABL1-negative myeloproliferative neoplasms: a review of JAK inhibitors in the therapeutic armamentarium
Martin Griesshammer et al.
EXPERT OPINION ON PHARMACOTHERAPY (2017)
Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study
Francesco Passamonti et al.
LANCET ONCOLOGY (2017)
Pegylated interferon alfa-2a in patients with essential thrombocythaemia or polycythaemia vera: a post-hoc, median 83 month follow-up of an open-label, phase 2 trial
Lucia Masarova et al.
LANCET HAEMATOLOGY (2017)
Experience with ruxolitinib in the treatment of polycythaemia vera
Samah Alimam et al.
THERAPEUTIC ADVANCES IN HEMATOLOGY (2017)
The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
Daniel A. Arber et al.
BLOOD (2016)
Second line therapies in polycythemia vera: What is the optimal strategy after hydroxyurea failure?
Aziz Nazha et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2016)
Changes in quality of life and disease-related symptoms in patients with polycythemia vera receiving ruxolitinib or standard therapy
Ruben Mesa et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2016)
Ruxolitinib versus Standard Therapy for the Treatment of Polycythemia Vera
Alessandro M. Vannucchi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Management of symptoms in polycythemia vera and essential thrombocythemia patients
Deepti Radia et al.
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM (2015)
Therapeutic options for patients with polycythemia vera and essential thrombocythemia refractory/resistant to hydroxyurea
Matjaz Sever et al.
LEUKEMIA & LYMPHOMA (2014)
Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project
Giovanni Barosi et al.
BLOOD (2013)
Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study
A. Tefferi et al.
LEUKEMIA (2013)
Patients with polycythemia vera have worst impairment of quality of life among patients with newly diagnosed myeloproliferative neoplasms
Johanna Abelsson et al.
LEUKEMIA & LYMPHOMA (2013)
Cardiovascular Events and Intensity of Treatment in Polycythemia Vera
Roberto Marchioli et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Assessment and prognostic value of the European LeukemiaNet criteria for clinicohematologic response, resistance, and intolerance to hydroxyurea in polycythemia vera
Alberto Alvarez-Larran et al.
BLOOD (2012)
Combination treatment in vitro with Nutlin, a small-molecule antagonist of MDM2, and pegylated interferon-α 2a specifically targets JAK2V617F-positive polycythemia vera cells
Min Lu et al.
BLOOD (2012)
Myeloproliferative Neoplasm (MPN) Symptom Assessment Form Total Symptom Score: Prospective International Assessment of an Abbreviated Symptom Burden Scoring System Among Patients With MPNs
Robyn M. Emanuel et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): International Prospective Validation and Reliability Trial in 402 patients
Robyn Scherber et al.
BLOOD (2011)
Philadelphia-Negative Classical Myeloproliferative Neoplasms: Critical Concepts and Management Recommendations From European LeukemiaNet
Tiziano Barbui et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
JAK2 allele burden in the myeloproliferative neoplasms: effects on phenotype, prognosis and change with treatment
Alessandro M. Vannucchi et al.
THERAPEUTIC ADVANCES IN HEMATOLOGY (2011)
A unified definition of clinical resistance and intolerance to hydroxycarbamide in polycythaemia vera and primary myelofibrosis: results of a European LeukemiaNet (ELN) consensus process
Giovanni Barosi et al.
BRITISH JOURNAL OF HAEMATOLOGY (2010)
Hydroxyurea does not appreciably reduce JAK2 V617F allele burden in patients with polycythemia vera or essential thrombocythemia
Elisabetta Antonioli et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2010)
Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference
Giovanni Barosi et al.
BLOOD (2009)
The Myelofibrosis Symptom Assessment Form (MFSAF): An evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosis
Ruben A. Mesa et al.
LEUKEMIA RESEARCH (2009)
Interferon-α therapy in bcr-abl-negative myeloproliferative neoplasms
J-J Kiladjian et al.
LEUKEMIA (2008)
Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms:: a critical reappraisal
A. M. Vannucchi et al.
LEUKEMIA (2008)
Prevalence and clinicopathologic correlates of JAK2 exon 12 mutations in JAK2V617F-negative polycythemia vera
A. Pardanani et al.
LEUKEMIA (2007)
Prospective identification of high-risk polycythemia vera patients based on JAK2V617F allele burden
A. M. Vannucchi et al.
LEUKEMIA (2007)
Share Paper
